Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Microbiota in hematologic malignancies

Florent Malard • 8 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia

Florent Malard, MD, PhD, Saint-Antoine Hospital, Paris, France, tells us what he’s looking forward to at EHA 2020. Prof. Malard highlights a study on the role of microbiota in acute lymphoblastic leukemia (ALL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florent Malard

Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
0:55
Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
Florent Malard • 24 Mar 2026
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
1:50
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
Florent Malard • 24 Mar 2026
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
2:08
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
Florent Malard • 7 Dec 2025

Related Videos

Referral and transplant-timing decisions in AML: advice for community physicians
1:37
Referral and transplant-timing decisions in AML: advice for community physicians
Iskra Pusic • 11 Sep 2026
Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Integrating molecular testing into frontline treatment decisions in CLL
2:11
Integrating molecular testing into frontline treatment decisions in CLL
Kerry Rogers • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals